CAMPTOSAR

LOE Approaching

irinotecan hydrochloride

NDAINJECTIONINJECTABLEPriority Review
Approved
Jun 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8

Mechanism of Action

camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand…

Clinical Trials (5)

NCT03245450Phase 1/2Completed

Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

Started Mar 2018
40 enrolled
Refractory or Recurrent Solid TumorsRhabdomyosarcomaNon-Rhabdomyosarcoma Soft Tissue Sarcoma+1 more
NCT02192359Phase 1Active Not Recruiting

Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

Started Mar 2016
NCT02049593Phase 1Completed

PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Started Jun 2014
44 enrolled
Metastatic CancerUnspecified Adult Solid Tumor
NCT01787500Phase 1Active Not Recruiting

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Started Feb 2013
33 enrolled
BRAF NP_004324.2:p.V600XKRAS wt AlleleMetastatic Malignant Solid Neoplasm+4 more
NCT01767194Phase 2Completed

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

Started Feb 2013
73 enrolled
GanglioneuroblastomaRecurrent Neuroblastoma